Athira Pharma Inc. (ATHA): Price and Financial Metrics

Athira Pharma Inc. (ATHA): $2.64

0.08 (+3.13%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add ATHA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#165 of 360

in industry

ATHA Price/Volume Stats

Current price $2.64 52-week high $4.30
Prev. close $2.56 52-week low $1.33
Day low $2.51 Volume 97,700
Day high $2.67 Avg. volume 336,035
50-day MA $2.32 Dividend yield N/A
200-day MA $2.39 Market Cap 101.19M

ATHA Stock Price Chart Interactive Chart >


Athira Pharma Inc. (ATHA) Company Bio


Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company was founded by Leen Kawas and Joseph Harding in 2011 and is headquartered in Seattle, WA.


ATHA Latest News Stream


Event/Time News Detail
Loading, please wait...

ATHA Latest Social Stream


Loading social stream, please wait...

View Full ATHA Social Stream

Latest ATHA News From Around the Web

Below are the latest news stories about ATHIRA PHARMA INC that investors may wish to consider to help them evaluate ATHA as an investment opportunity.

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 26, 2023

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases Cognitive measures in the 40 mg dose group bolster confidence in ongoing Phase 2/3 LIFT-AD clinical trial of fosgonimeton in Alzheimer’s disease, which is on track to complete enrollment in early 2024 and report topline results in second half of 2024 BOTHELL, Wash., Dec. 12, 2023 (GLOBE NEWSWI

Yahoo | December 12, 2023

Sidoti Events, LLC's Virtual December Small-Cap Conference

NEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December ...

Yahoo | December 5, 2023

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer’s diseaseBOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Sidoti Decemb

Yahoo | November 29, 2023

Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND

Presentation to highlight preclinical data from ATH-1105, Athira’s potential treatment candidate for amyotrophic lateral sclerosis (ALS)BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that a symposium presentation highlighting data from preclinical studies of ATH-1105 as a potential treatment candidate f

Yahoo | November 28, 2023

Read More 'ATHA' Stories Here

ATHA Price Returns

1-mo 37.50%
3-mo -32.82%
6-mo 72.55%
1-year 0.38%
3-year -85.53%
5-year N/A
YTD 8.64%
2023 -23.34%
2022 -75.67%
2021 -61.96%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!